Indivior strikes agreement with Actavis over patent dispute

Indivior announced significant agreement in its ongoing patent dispute with Actavis Laboratories UT, a subsidiary of Teva Pharmaceuticals, on Wednesday.

The FTSE 250 company said it had entered a settlement agreement with Actavis, resolving the patent disputes related to Actavis's Abbreviated New Drug Application (ANDA) for generic buprenorphine and naloxone sublingual film.

Under the settlement, Indivior granted Actavis a licence to its US patent to enable Actavis to launch the generic film products specified in its ANDA within the US.

However, the launch could not happen before 31 January 2025, unless the unexpired patent claims were determined to be invalid or unenforceable before that date in a final judicial decision.

At 0848 GMT, shares in Indivior were up 3.4% at 1,186p.

Reporting by Josh White for Sharecast.com.